MEDIA ALERT :Catalent Boston Announces Technology Upgrade to meet the needs of Global Customers

Catalent is proud to announce it has completed the upgrade of its large-scale spray drying unit (GEA PSD-4) at its Boston, Massachusetts facility, supporting enhanced spray-drying services across late-stage to commercialization projects to meet the needs of global customers.

This upgrade enables the company to offer manufacturing services for late-stage clinical supplies, registration, and commercialization through building on current services through the addition of Amorphous Spray Dried Dispersions (SDDs). SDD is a widely adopted technology for improving the bioavailability of oral dosage forms. This technology allows the enhancement of poorly soluble compounds within the Biopharmaceutics Classification System (BCS) Class II and it expands the wide range of advanced technologies that Catalent offers for bioavailability enhancement such as Lipid-based formulations, Hot Melt Extrusion and Particle Sizing.

“The Boston site is excited with the recent significant investments in multi-solvent capabilities, cyclones, and secondary dryers complementing Catalent’s formulation development and early clinical supplies of SDDs. It also ensures supply chain continuity within Catalent’s global network of downstream dosage form manufacturing facilities, positioning Catalent exceptionally well to meet the needs of global customers with end-to-end SDD solutions” commented Gordon Ashton, Site General Manager.

About Catalent Boston

Catalent Boston is a state-of-the-art global Center of Excellence for spray dry dispersion and Dry Powder Inhaler (DPI) capsule manufacture and packaging. Acquired for 80 million by Catalent in 2021, the site was previously owned by Acorda Therapeutics and has the largest capacity and most unique features of spray drying for inhaled powders. The site grew its overall capabilities through the acquisition of Pharmatek Laboratories in 2016 and Juniper Pharmaceuticals in 2018.